Alzheimer's Disease and Dementia
Ronald Petersen, MD, PhD, discusses the implications of Eli Lilly's failed solanezumab trial on the future of Alzheimer's disease research.
In people who are genetically at-risk for Alzheimer's, concussions appear to accelerate brain changes associated with the disease.
Increasing severity of AD pathology inversely correlated to decreases in time from motor symptoms to dementia onset and death.
Hormone therapy may reduce risk for death from vascular dementia in older women.
Amyloid beta protein accumulation was present in the hearts of patients with Alzheimer's disease.
There is a clear lack of evidence in the pharmacologic guidance of sleep problems in dementia.
Patients with Alzheimer's disease tended to have increased thickness in the wall of their left ventricle.
The present findings, in combination with those from prior observational research, provide a solid rationale for further randomized trials.
There seems to be no effect on everyday functioning.
Eli Lilly's investigational Alzheimer's drug failed to meet the primary end point in the phase 3 EXPEDITION3 trial.
Higher levels of education and better management of cardiovascular risk factors may have contributed to this improvement.
Patients with mild cognitive impairment with preserved hippocampal volume are at increased risk for dementia with Lewy bodies vs Alzheimer disease.
Future studies should investigate other neuropsychiatric factors for their impact on early signs of AD.
Sudden blood pressure drops may lead to hypoxia, which has detrimental effects on brain tissue.
Neuroimaging and if necessary, genetic testing, can help to confirm an FTD diagnosis.
Researchers hypothesize that thyroid function affects dementia risk through nonvascular pathways.
Previous studies have investigated the effects of exposing aged mice to the blood of young mice through heterochronic parabiosis or via injection of young blood plasma.
An update on the latest research developments examining the connection between alcohol consumption and Alzheimer's disease.
Suspected non-Alzheimer disease pathophysiology (SNAP) does not appear to be linked to early Alzheimer disease processes.
Weaker handgrip was also associated with an elevated risk of stroke.
The treatment was generally safe, but benefit varied across age groups.
The checklist may help identify those in the early stages of neurodegenerative disease.
Cases of all-cause dementia and Alzheimer's did not significantly differ between study groups.
According to a 2010 report based on a survey of caregivers of people with DLB, 78% of cases were initially misdiagnosed.
Findings suggest that interactions between beta-amyloid and tau lead to neurodegeneration in Alzheimer's.
It will take a lot of work to change the prescribing culture in adult care.
Those with ε4 homozygosity have the highest odds ratio of the earliest Alzheimer's onset.
This is the first study to examine the role of CSF biomarkers in the diagnosis of patients with cognitive symptoms and psychiatric disorders in routine daily clinical practice.
PGRS was also associated with hippocampal volume in younger participants.
Microbleeds were prevalent in 15.3% of the cohort.
Neurology Advisor Articles
- Self-Controlled Electric Stimulation a Good Alternative to Drug Therapy for Migraine
- Elevated Copeptin Levels in Acute Headache May Signify More Serious Etiology
- New Sleep Apnea Clinical Practice Guidelines
- Patent Foramen Ovale Closure Reduces Stroke Risk in Patients With Inherited Thrombophilias
- Neural Targeting Spinal Cord Stimulation Superior for Axial Low Back Pain
- DHA Supplementation Has No Impact on IQ in Offspring
- Safinamide Approved as Adjunctive Therapy for Parkinson's
- International League Against Epilepsy Updates Epilepsy Classification System
- Depression, Schizophrenia Identified With Objective Blood Biomarker
- Autoimmune Disease Hospitalization Linked to Future Dementia Risk